Synopsis
Synopsis
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Acemetacin Heumann
2. Acemetacin Intermuti
3. Acemetacin Monohydrate
4. Acemetacin Sodium
5. Acemetacin Stada
6. Acemetacin Von Ct
7. Acemetadoc
8. Acephlogont
9. Azeat
10. Emflex
11. Espledol
12. Indomethacin Carboxymethyl Ester
13. Oldan
14. Rantodil
15. Rantudil
16. Tvx 1322
1. 53164-05-9
2. Rantudil
3. Emflex
4. Acemix
5. Acemetacinum
6. Acemetacina
7. Acemetacine
8. Tvx 1322
9. Indomethacin Carboxymethyl Ester
10. Tvx 3322
11. K-708
12. 1h-indole-3-acetic Acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, Carboxymethyl Ester
13. K 708
14. Indometacin Glycolic Ester
15. Indomethacin Glycolic Ester
16. Nsc-757413
17. Indometacin Carboxymethyl Ester
18. Chembl189171
19. Chebi:31162
20. 5v141xk28x
21. 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic Acid
22. 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-acetic Acid Carboxymethyl Ester
23. Ncgc00016868-09
24. Aximeixin
25. Rheumibis
26. 2-[2-[1-(4-chloro-2,3,5,6-tetradeuteriobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic Acid
27. Cas-53164-05-9
28. Dsstox_cid_2540
29. 1-[p-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic Acid Carboxymethyl Ester
30. 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic Acid Ester With Glycolic Acid
31. Dsstox_rid_76618
32. Dsstox_gsid_22540
33. Bay F 4975
34. Solart
35. Acemetacine [inn-french]
36. Acemetacinum [inn-latin]
37. Acemetacina [inn-spanish]
38. 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic Acid Carboxymethyl Ester
39. 2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl)acetoxy)acetic Acid
40. Smr000058409
41. Sr-01000000070
42. Einecs 258-403-4
43. Brn 0501672
44. Acemetacin [inn:ban:jan]
45. Unii-5v141xk28x
46. Rantudil (tn)
47. Prestwick_669
48. Acemetacin (emflex)
49. Mfcd00151473
50. Spectrum_000428
51. Acemetacin [mi]
52. Acemetacin [inn]
53. Acemetacin [jan]
54. Prestwick0_000296
55. Prestwick1_000296
56. Prestwick2_000296
57. Prestwick3_000296
58. Spectrum2_001162
59. Spectrum3_001868
60. Spectrum4_000803
61. Spectrum5_001385
62. ((1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl)acetoxy)acetic Acid
63. Acemetacin (jp17/inn)
64. (1-(p-chlorbenzoyl)-5-methoxy-2-methylindol-3-acetoxy)essigsaeure [german]
65. 2-(2-(1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl)acetoxy)acetic Acid
66. Acemetacin [mart.]
67. Acemetacin [who-dd]
68. Bay-f-4975
69. Schembl23843
70. Bspbio_000232
71. Bspbio_003316
72. Kbiogr_001285
73. Kbioss_000908
74. 5-22-05-00241 (beilstein Handbook Reference)
75. Mls000028440
76. Mls006010622
77. Divk1c_000490
78. Spectrum1500666
79. Spbio_001143
80. Spbio_002451
81. Acemetacin, Analytical Standard
82. Bpbio1_000256
83. Dtxsid7022540
84. Hms501i12
85. Kbio1_000490
86. Kbio2_000908
87. Kbio2_003476
88. Kbio2_006044
89. Kbio3_002818
90. Acemetacin [ep Monograph]
91. Ninds_000490
92. Hms1568l14
93. Hms1921a08
94. Hms2090e21
95. Hms2095l14
96. Hms2230g08
97. Hms3372k20
98. Hms3656e22
99. Hms3712l14
100. Hms3884p10
101. Pharmakon1600-01500666
102. Zinc601272
103. Bcp13127
104. Hy-b0482
105. Tvx-1322
106. Tox21_113473
107. (1-(p-chlorbenzoyl)-5-methoxy-2-methylindol-3-acetoxy)essigsaeure
108. Bdbm50336272
109. Ccg-39550
110. Nsc757413
111. S2602
112. Akos015895194
113. Tox21_113473_1
114. Ab03974
115. Db13783
116. Nsc 757413
117. Tv-1322
118. {2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]acetoxy}acetic Acid
119. Idi1_000490
120. Ncgc00016868-01
121. Ncgc00016868-02
122. Ncgc00016868-03
123. Ncgc00016868-04
124. Ncgc00016868-05
125. Ncgc00016868-06
126. Ncgc00016868-07
127. Ncgc00016868-08
128. Ncgc00016868-11
129. Ncgc00016868-12
130. Ncgc00022084-03
131. Ncgc00022084-04
132. Ncgc00022084-05
133. Ncgc00022084-06
134. Ncgc00022084-07
135. Bs-16970
136. Sbi-0051585.p002
137. Db-052263
138. A2452
139. Ab00052149
140. Ft-0630659
141. Sw196824-3
142. D01582
143. D88520
144. Ab00052149-15
145. Ab00052149_16
146. Ab00052149_17
147. From D:/data/p.sapui/gsas_26052012/ps1.cif
148. 164a059
149. A936725
150. Q2723146
151. Sr-01000000070-2
152. Sr-01000000070-3
153. Brd-k67563174-001-05-1
154. Brd-k67563174-001-09-3
155. Acemetacin, European Pharmacopoeia (ep) Reference Standard
156. [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetoxyacetic Acid
157. [1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetoxy]-acetic Acid
158. [({1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetyl)oxy]acetic Acid
159. [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic Acid Carboxymethyl Ester
160. [({1-[(4-chlorophenyl)carbonyl]-2-methyl-5-(methyloxy)-1h-indol-3-yl}acetyl)oxy]acetic Acid
161. [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetoxyacetic Acid[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetoxyacetic Acid
Molecular Weight | 415.8 g/mol |
---|---|
Molecular Formula | C21H18ClNO6 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 415.0822650 g/mol |
Monoisotopic Mass | 415.0822650 g/mol |
Topological Polar Surface Area | 94.8 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 620 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Acemetacin is not FDA, Canada or EMA approved, but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis, osteoarthritis, low back pain and post-surgical pain. It is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis, treatment of ankylosing spondylitis, treatment of irritation in the joints and spinal column caused by degenerative disorders, treatment of inflammatory soft-tissue rheumatism syndrome and painful swelling and inflammation caused by injury.
The effect of acemetacin causes a weak reduction of prostaglandin synthesis which generates an anti-inflammatory and analgesic effect. The weak inhibition of prostaglandin reduces significantly the damage caused in the mucous membrane of the gastrointestinal tract. Studies have shown that acemetacin strongly inhibits the release of histamine from mast cells and the generation of hyperthermia. Acemetacin effect also causes changes in systolic and diastolic blood pressure as well as inhibition of platelet aggregation.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
M01AB11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01A - Antiinflammatory and antirheumatic products, non-steroids
M01AB - Acetic acid derivatives and related substances
M01AB11 - Acemetacin
Absorption
After 8 days of oral administration twice daily of acemetacin there was an age-dependant Cmax of 276.8 ng/ml in elderly compared to 187 ng/ml for younger individuals. There was also a Tmax of 2.5 h and AUC in a range of 483-712 ng h/ml. The bioavailability of acemetacin after repeated doses is aproximately 66% in plasma and 64% in urine.
Route of Elimination
The elimination of acemetacin is divided in renal elimination that covers 40% of the complete administered dose and the restant 60% is excreted in feces.
Volume of Distribution
The apparent volume of distribution of acemetacin is in a range of 0.5-0.7 L/kg.
Clearance
Intravenous administration of acemetacin in healthy subjects reported a clearance rate of 4.59 ml min/kg.
Acemetacin is highly metabolized and degraded by esterolytic cleavage to form its major and active metabolite indometacin. It presents other inactive metabolites made by reaction of O-demethylation, N-desacylation and part of them are also transformed by conjugation with glucuronic acid.
The elimination half-life of acemetacin after steady-state is 4.5 hours.
Acemetacin is a non-selective inhibitor of the production of pro-inflammatory mediators derived from the action of the enzyme COX. COX is essential for the synthesis of prostaglandin E2 and F2 which are molecules derived from fatty acids and stored in the cell membrane. Acetometacine is metabolized and forms its major metabolite indometacin which is also a non-selective inhibitor of COX and exhibits the capacity to inhibit the motility of polymorphonuclear leukocytes and decreased cerebral flow by modulating the nitric oxide pathway and vasoconstriction.
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Acemetacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acemetacin, including repackagers and relabelers. The FDA regulates Acemetacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acemetacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Acemetacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Acemetacin supplier is an individual or a company that provides Acemetacin active pharmaceutical ingredient (API) or Acemetacin finished formulations upon request. The Acemetacin suppliers may include Acemetacin API manufacturers, exporters, distributors and traders.
click here to find a list of Acemetacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Acemetacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Acemetacin active pharmaceutical ingredient (API) in detail. Different forms of Acemetacin DMFs exist exist since differing nations have different regulations, such as Acemetacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Acemetacin DMF submitted to regulatory agencies in the US is known as a USDMF. Acemetacin USDMF includes data on Acemetacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Acemetacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Acemetacin suppliers with USDMF on PharmaCompass.
A Acemetacin CEP of the European Pharmacopoeia monograph is often referred to as a Acemetacin Certificate of Suitability (COS). The purpose of a Acemetacin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Acemetacin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Acemetacin to their clients by showing that a Acemetacin CEP has been issued for it. The manufacturer submits a Acemetacin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Acemetacin CEP holder for the record. Additionally, the data presented in the Acemetacin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Acemetacin DMF.
A Acemetacin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Acemetacin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Acemetacin suppliers with CEP (COS) on PharmaCompass.
A Acemetacin written confirmation (Acemetacin WC) is an official document issued by a regulatory agency to a Acemetacin manufacturer, verifying that the manufacturing facility of a Acemetacin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Acemetacin APIs or Acemetacin finished pharmaceutical products to another nation, regulatory agencies frequently require a Acemetacin WC (written confirmation) as part of the regulatory process.
click here to find a list of Acemetacin suppliers with Written Confirmation (WC) on PharmaCompass.
Acemetacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acemetacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acemetacin GMP manufacturer or Acemetacin GMP API supplier for your needs.
A Acemetacin CoA (Certificate of Analysis) is a formal document that attests to Acemetacin's compliance with Acemetacin specifications and serves as a tool for batch-level quality control.
Acemetacin CoA mostly includes findings from lab analyses of a specific batch. For each Acemetacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acemetacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Acemetacin EP), Acemetacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acemetacin USP).
LOOKING FOR A SUPPLIER?